Market Place
Sourcing Support
Theolytics Doses First Patient in Phase 1 Ovarian Cancer Trial
28 Apr 2026 //
GLOBENEWSWIRE
Theolytics Secures €8M Grant To Advance THEO-260 Phase 2 Study
04 Mar 2026 //
PHARMIWEB
Theolytics Showcases THEO-260 In Ovarian Cancer Trial At ESMO
13 Oct 2025 //
GLOBENEWSWIRE
Theolytics Names Matilde Saggese, MD, Chief Medical Officer
07 Oct 2025 //
GLOBENEWSWIRE
Theolytics Appoints David Apelian MD, PhD, MBA as CEO
17 Dec 2024 //
GLOBENEWSWIRE
Theolytics Doses 1st Patient in Ph I/IIa of THEO-260 in Cancer
19 Nov 2024 //
GLOBENEWSWIRE
Theolytics Awarded Significant £2M for Cancer Therapeutics Grant from UK
02 Sep 2024 //
GLOBENEWSWIRE
Theolytics successfully closes latest financing raising total of £19M
17 Apr 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.